We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RGLS
2901
DELISTED
Regulus Therapeutics
RGLS
$55K ﹤0.01%
18,460
HIL
2902
DELISTED
Hill International, Inc. Common Stock
HIL
$54K ﹤0.01%
33,200
CLSD
2903
DELISTED
Clearside Biomedical
CLSD
$53K ﹤0.01%
1,547
+754
+95% +$22.6K
CRDF icon
2904
Cardiff Oncology
CRDF
$79.4M
$53K ﹤0.01%
21,480
+800
+4% +$2.83K
VRAY
2905
DELISTED
ViewRay, Inc.
VRAY
$52K ﹤0.01%
+13,313
New +$56.7K
DS
2906
DELISTED
Drive Shack Inc.
DS
$52K ﹤0.01%
33,836
-5,394,036
-99% -$7.33M
OUST icon
2907
Ouster
OUST
$3.36B
$51K ﹤0.01%
1,144
+105
+10% +$3.88K
IDN icon
2908
Intellicheck
IDN
$75.1M
$50K ﹤0.01%
19,500
-7,900
-29% -$28.8K
ALGS icon
2909
Aligos Therapeutics
ALGS
$42.2M
$49K ﹤0.01%
903
+20
+2% +$1.6K
RIDE
2910
DELISTED
Lordstown Motors Corp. Class A Common Stock
RIDE
$48K ﹤0.01%
929
-464
-33% -$20.1K
BRN icon
2911
Barnwell Industries
BRN
$13.9M
$47K ﹤0.01%
18,200
FPAY
2912
DELISTED
FlexShopper
FPAY
$47K ﹤0.01%
27,700
AIOT
2913
PowerFleet Inc
AIOT
$417M
$47K ﹤0.01%
15,900
IDEX
2914
DELISTED
Ideanomics, Inc. Common Stock
IDEX
$47K ﹤0.01%
336
+89
+36% +$11.4K
VLTA
2915
DELISTED
Volta Inc.
VLTA
$46K ﹤0.01%
+15,000
New +$72.1K
AFMD
2916
DELISTED
Affimed
AFMD
$45K ﹤0.01%
+1,037
New +$45.1K
AKBA icon
2917
Akebia Therapeutics
AKBA
$247M
$45K ﹤0.01%
62,607
+18,149
+41% +$38.8K
PHUN icon
2918
Phunware
PHUN
$43.4M
$45K ﹤0.01%
324
-196
-38% -$27.2K
KG
2919
Kestrel Group
KG
$67.4M
$44K ﹤0.01%
907
+71
+8% +$3.74K
NGNE icon
2920
Neurogene
NGNE
$734M
$44K ﹤0.01%
1,172
+370
+46% +$21.6K
STIM icon
2921
Neuronetics
STIM
$228M
$42K ﹤0.01%
+13,813
New +$46.7K
TUSK icon
2922
Mammoth Energy Services
TUSK
$158M
$38K ﹤0.01%
18,000
CTXR icon
2923
Citius Pharmaceuticals
CTXR
$19.9M
$37K ﹤0.01%
836
+132
+19% +$5.21K
ZYNE
2924
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$37K ﹤0.01%
18,200
BRDS
2925
DELISTED
Bird Global, Inc.
BRDS
$37K ﹤0.01%
+596
New +$52.9K

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.